IZ
Therapeutic Areas
Evofem Biosciences Pipeline
| Drug | Indication | Phase |
|---|---|---|
| Phexxi® (lactic acid, citric acid and potassium bitartrate) | On-demand prescription contraception | Approved |
| Solosec® (secnidazole) | Bacterial vaginosis and trichomoniasis | Approved |
| EVO200 | Prevention of recurrent Bacterial Vaginosis (BV) | Phase 1 |
| MPT Product Candidate (with OB-002) | Prevention of human immunodeficiency virus (HIV) | Preclinical |
Leadership Team at Evofem Biosciences
SP
Saundra Pelletier
Chief Executive Officer, President, Executive Director and interim Chair of the Board
KG
Kathy Gallo-Doyle
Senior Vice President, Commercial Operations
AR
Amy Raskopf
Chief Business Development Officer
ET
Ellen Thomas
Chief of Staff
KK
Kim Kamdar, Ph.D.
Member of the Board of Directors; Chair, Governance and Nominating Committee
TO
Tony O'Brien
Member of the Board of Directors